Stephen J. DiPalma - 17 May 2021 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Reporting relationship: Interim CFO
Issuer ticker: INZY
Reported as of: 17 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2021, 16:18:59 UTC
Next SEC filing: 24 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Damon Banks, as attorney-in-fact for Stephen DiPalma

Key filing fact

Stephen J. DiPalma filed Form 4 for Inozyme Pharma, Inc. (INZY) on 18 May 2021.

Key facts

This page summarizes Stephen J. DiPalma's Form 4 filing for Inozyme Pharma, Inc. (INZY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 May 2021, 16:18.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INZY transaction Derivative

Stock option (Right to Buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 17 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $15.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on May 17, 2021 and will vest as to 50% of the shares underlying the option on the date that is 180 days following the grant date and as to the remaining 50% of the shares underlying the option on the first anniversary of the grant date, provided Mr. DiPalma is providing services to the Company on such dates.